TEST BANK n
Pharmacotherapeutics nfor nAdvanced nPractice nNurse nPrescribers, n6th
nEdition
Author: nTeri nMoser nWoo nand nWendy nL. nWright
, TABLE nOF nCONTENT
Chapter n1. nThe nRole nof nthe nAdvanced nPractice nNurse nas nPrescriber ........................................................... 4
Chapter n2. nReview nof nBasic nPrinciples nof nPharmacology............................................................................... 5
Chapter n3. nRational nDrug nSelection................................................................................................................. 11
Chapter n4. nLegal nand nProfessional nIssues nin nPrescribing .............................................................................. 14
Chapter n5. nAdverse nDrug nReactions ................................................................................................................ 16
Chapter n6. nAn nIntroduction nto nPharmacogenomics ........................................................................................ 19
Chapter n7. nNutrition nand nNutraceuticals .......................................................................................................... 22
Chapter n8. nHerbal nTherapies ............................................................................................................................. 28
Chapter n9. nCannabis .......................................................................................................................................... 31
Chapter n10. nPharmacoeconomics ...................................................................................................................... 35
Chapter n11. nDrugs nAffecting nthe nAutonomic nNervous nSystem .................................................................... 38
Chapter n12. nDrugs nAffecting nthe nCentral nNervous nSystem .......................................................................... 45
Chapter n13. nDrugs nAffecting nthe nCardiovascular nand nRenal nSystems ......................................................... 53
Chapter n14. nDrugs nAffecting nthe nRespiratory nSystem ................................................................................... 61
Chapter n15. nDrugs nAffecting nthe nHematological nSystem .............................................................................. 65
Chapter n16. nDrugs nAffecting nthe nImmune nSystem: nVaccines nand nImmunoglobulins ................................. 69
Chapter n17. nDrugs nAffecting nthe nImmune nSystem: nImmunomodulators ...................................................... 75
Chapter n18. nDrugs nAffecting nthe nGastrointestinal nSystem ............................................................................ 77
Chapter n19. nDrugs nAffecting nthe nEndocrine nSystem: nPancreatic nHormones nand nAntidiabetic nDrugs ........ 80
Chapter n20. nDrugs nAffecting nthe nEndocrine nSystem: nPituitary, nThyroid, nand nAdrenal nDrugs ................. 83
Chapter n21. nDrugs nAffecting nthe nReproductive nSystem ................................................................................ 86
Chapter n22. nDrugs nAffecting nthe nBones nand nJoints ...................................................................................... 92
Chapter n23. nDrugs nAffecting nthe nIntegumentary nSystem .............................................................................. 96
Chapter n24. nDrugs nUsed nto nTreat nBacterial nInfections ............................................................................... 101
Chapter n25. nDrugs nUsed nto nTreat nViral, nFungal, nand nProtozoal nInfections.............................................. 105
Chapter n26. nDrugs nUsed nto nTreat nInflammatory nProcesses ........................................................................ 108
Chapter n27. nDrugs nUsed nto nTreat nEye nand nEar nDisorders ......................................................................... 111
Chapter n28. nAnemia ........................................................................................................................................ 113
Chapter n29. nAnxiety nand nDepression ............................................................................................................. 116
Chapter n30. nAttention nDeficit-Hyperactivity nDisorder .................................................................................. 120
Chapter n31. nAsthma nand nAllergy ................................................................................................................... 122
Chapter n32. nChronic nObstructive nPulmonary nDisease .................................................................................. 125
Chapter n33. nContraception ............................................................................................................................... 127
Chapter n34. nCOVID-19: nAcute nand nChronic ................................................................................................ 130
Chapter n35. nDermatological nConditions ......................................................................................................... 134
Chapter n36. nDiabetes nManagement ................................................................................................................ 138
Chapter n37. nGastroesophageal nReflux nand nPeptic nUlcer nDisease ............................................................... 146
Chapter n38. nHeadaches .................................................................................................................................... 149
Chapter n39. nHeart nFailure ............................................................................................................................... 153
Chapter n40. nHIV nDisease nand nAcquired nImmunodeficiency nSyndrome ..................................................... 158
Chapter n41. nMenopausal nHormone nTherapy ................................................................................................. 161
,Chapter n42. nHyperlipidemia ............................................................................................................................ 164
Chapter n43. nHypertension ................................................................................................................................ 169
Chapter n44. nHyperthyroidism nand nHypothyroidism ...................................................................................... 174
Chapter n45. nObesity ......................................................................................................................................... 177
Chapter n46. nPain nManagement: nAcute nand nChronic nPain ........................................................................... 181
Chapter n47. nPneumonia ................................................................................................................................... 185
Chapter n48. nSexually nTransmitted nDiseases nand nVaginitis .......................................................................... 187
Chapter n49. nSubstance nUse nDisorders ........................................................................................................... 190
Chapter n50. nTuberculosis ................................................................................................................................. 195
Chapter n51. nUpper nRespiratory nTract nInfection, nPharyngitis, nSinusitis, nOtitis nMedia, nand nOtitis nExterna197
Chapter n52. nUrinary nTract nInfections ............................................................................................................ 200
Chapter n53. nWomen nas nPatients..................................................................................................................... 203
Chapter n54. nMen nas nPatients .......................................................................................................................... 207
Chapter n55. nPediatric nPatients ........................................................................................................................ 209
Chapter n57. nGeriatric nPatients ........................................................................................................................ 213
, Woo 1
Pharmacotherapeutics nfor nAPN nPrescribers, Ch01
n6e
Chapter n1. nThe nRole nof nthe nAdvanced nPractice nNurse nas nPrescriber
MULTIPLE nCHOICE
1. Nurse npractitioner nprescriptive nauthority nis nregulated nby:
A. The nNational nCouncil nof nState nBoards nof nNursing
B. The nU.S. nDrug nEnforcement nAdministration
C. The nState nBoard nof nNursing nfor neach nstate
D. The nState nBoard nof nPharmacy
ANS: n C PTS: n n1
2. The nbenefits nto nthe npatient nof nhaving nan nadvanced npractice nregistered nnurse n(APRN)
nprescriber ninclude:
A. Nurses nknow nmore nabout npharmacology nthan nother nprescribers nbecause nthey
ntake nit nboth nin ntheir nbasic nnursing nprogram nand nin ntheir nAPRN nprogram.
B. Nurses ncare nfor nthe npatient nfrom na nholistic napproach nand ninclude nthe
npatient nin ndecision-making nregarding ntheir ncare.
C. APRNs nare nless nlikely nto nprescribe nnarcotics nand nother ncontrolled nsubstances.
D. APRNs nare nable nto nprescribe nindependently nin nall nstates, nwhereas na
nphysician’s nassistant nneeds nto nhave na nphysician nsupervising ntheir
npractice.
ANS: n B PTS: n n1
3. Clinical njudgment nin nprescribing nincludes:
A. Factoring nin nthe ncost nto nthe npatient nof nthe nmedication nprescribed
B. Always nprescribing nthe nnewest nmedication navailable nfor nthe ndisease nprocess
C. Handing nout ndrug nsamples nto npoor npatients
D. Prescribing nall ngeneric nmedications nto ncut ncosts
ANS: n A PTS: n n1
4. The nprocess nfor nchoosing nan neffective ndrug nfor na ndisorder nincludes:
A. Asking nthe npatient nwhat ndrug nthey nthink nwould nwork nbest nfor nthem
B. Consulting nnationally nrecognized nguidelines nfor ndisease nmanagement
C. Prescribing nmedications nthat nare navailable nas nsamples nbefore nwriting na nprescription
D. Following nU.S. nDrug nEnforcement nAdministration nguidelines nfor nprescribing
ANS: n B PTS: n n1
5. Nonintentional nnonadherence nof ndrug ntherapy nmay noccur ndue nto:
A. Belief nthat nmedication ndoes nnot nwork
B. Adverse ndrug nreactions
C. Chronic nconditions nthat nrequire ndaily ntherapy
D. Forgetfulness nor ndistraction
ANS: n D PTS: n n1
Pharmacotherapeutics nfor nAdvanced nPractice nNurse nPrescribers, n6th
nEdition
Author: nTeri nMoser nWoo nand nWendy nL. nWright
, TABLE nOF nCONTENT
Chapter n1. nThe nRole nof nthe nAdvanced nPractice nNurse nas nPrescriber ........................................................... 4
Chapter n2. nReview nof nBasic nPrinciples nof nPharmacology............................................................................... 5
Chapter n3. nRational nDrug nSelection................................................................................................................. 11
Chapter n4. nLegal nand nProfessional nIssues nin nPrescribing .............................................................................. 14
Chapter n5. nAdverse nDrug nReactions ................................................................................................................ 16
Chapter n6. nAn nIntroduction nto nPharmacogenomics ........................................................................................ 19
Chapter n7. nNutrition nand nNutraceuticals .......................................................................................................... 22
Chapter n8. nHerbal nTherapies ............................................................................................................................. 28
Chapter n9. nCannabis .......................................................................................................................................... 31
Chapter n10. nPharmacoeconomics ...................................................................................................................... 35
Chapter n11. nDrugs nAffecting nthe nAutonomic nNervous nSystem .................................................................... 38
Chapter n12. nDrugs nAffecting nthe nCentral nNervous nSystem .......................................................................... 45
Chapter n13. nDrugs nAffecting nthe nCardiovascular nand nRenal nSystems ......................................................... 53
Chapter n14. nDrugs nAffecting nthe nRespiratory nSystem ................................................................................... 61
Chapter n15. nDrugs nAffecting nthe nHematological nSystem .............................................................................. 65
Chapter n16. nDrugs nAffecting nthe nImmune nSystem: nVaccines nand nImmunoglobulins ................................. 69
Chapter n17. nDrugs nAffecting nthe nImmune nSystem: nImmunomodulators ...................................................... 75
Chapter n18. nDrugs nAffecting nthe nGastrointestinal nSystem ............................................................................ 77
Chapter n19. nDrugs nAffecting nthe nEndocrine nSystem: nPancreatic nHormones nand nAntidiabetic nDrugs ........ 80
Chapter n20. nDrugs nAffecting nthe nEndocrine nSystem: nPituitary, nThyroid, nand nAdrenal nDrugs ................. 83
Chapter n21. nDrugs nAffecting nthe nReproductive nSystem ................................................................................ 86
Chapter n22. nDrugs nAffecting nthe nBones nand nJoints ...................................................................................... 92
Chapter n23. nDrugs nAffecting nthe nIntegumentary nSystem .............................................................................. 96
Chapter n24. nDrugs nUsed nto nTreat nBacterial nInfections ............................................................................... 101
Chapter n25. nDrugs nUsed nto nTreat nViral, nFungal, nand nProtozoal nInfections.............................................. 105
Chapter n26. nDrugs nUsed nto nTreat nInflammatory nProcesses ........................................................................ 108
Chapter n27. nDrugs nUsed nto nTreat nEye nand nEar nDisorders ......................................................................... 111
Chapter n28. nAnemia ........................................................................................................................................ 113
Chapter n29. nAnxiety nand nDepression ............................................................................................................. 116
Chapter n30. nAttention nDeficit-Hyperactivity nDisorder .................................................................................. 120
Chapter n31. nAsthma nand nAllergy ................................................................................................................... 122
Chapter n32. nChronic nObstructive nPulmonary nDisease .................................................................................. 125
Chapter n33. nContraception ............................................................................................................................... 127
Chapter n34. nCOVID-19: nAcute nand nChronic ................................................................................................ 130
Chapter n35. nDermatological nConditions ......................................................................................................... 134
Chapter n36. nDiabetes nManagement ................................................................................................................ 138
Chapter n37. nGastroesophageal nReflux nand nPeptic nUlcer nDisease ............................................................... 146
Chapter n38. nHeadaches .................................................................................................................................... 149
Chapter n39. nHeart nFailure ............................................................................................................................... 153
Chapter n40. nHIV nDisease nand nAcquired nImmunodeficiency nSyndrome ..................................................... 158
Chapter n41. nMenopausal nHormone nTherapy ................................................................................................. 161
,Chapter n42. nHyperlipidemia ............................................................................................................................ 164
Chapter n43. nHypertension ................................................................................................................................ 169
Chapter n44. nHyperthyroidism nand nHypothyroidism ...................................................................................... 174
Chapter n45. nObesity ......................................................................................................................................... 177
Chapter n46. nPain nManagement: nAcute nand nChronic nPain ........................................................................... 181
Chapter n47. nPneumonia ................................................................................................................................... 185
Chapter n48. nSexually nTransmitted nDiseases nand nVaginitis .......................................................................... 187
Chapter n49. nSubstance nUse nDisorders ........................................................................................................... 190
Chapter n50. nTuberculosis ................................................................................................................................. 195
Chapter n51. nUpper nRespiratory nTract nInfection, nPharyngitis, nSinusitis, nOtitis nMedia, nand nOtitis nExterna197
Chapter n52. nUrinary nTract nInfections ............................................................................................................ 200
Chapter n53. nWomen nas nPatients..................................................................................................................... 203
Chapter n54. nMen nas nPatients .......................................................................................................................... 207
Chapter n55. nPediatric nPatients ........................................................................................................................ 209
Chapter n57. nGeriatric nPatients ........................................................................................................................ 213
, Woo 1
Pharmacotherapeutics nfor nAPN nPrescribers, Ch01
n6e
Chapter n1. nThe nRole nof nthe nAdvanced nPractice nNurse nas nPrescriber
MULTIPLE nCHOICE
1. Nurse npractitioner nprescriptive nauthority nis nregulated nby:
A. The nNational nCouncil nof nState nBoards nof nNursing
B. The nU.S. nDrug nEnforcement nAdministration
C. The nState nBoard nof nNursing nfor neach nstate
D. The nState nBoard nof nPharmacy
ANS: n C PTS: n n1
2. The nbenefits nto nthe npatient nof nhaving nan nadvanced npractice nregistered nnurse n(APRN)
nprescriber ninclude:
A. Nurses nknow nmore nabout npharmacology nthan nother nprescribers nbecause nthey
ntake nit nboth nin ntheir nbasic nnursing nprogram nand nin ntheir nAPRN nprogram.
B. Nurses ncare nfor nthe npatient nfrom na nholistic napproach nand ninclude nthe
npatient nin ndecision-making nregarding ntheir ncare.
C. APRNs nare nless nlikely nto nprescribe nnarcotics nand nother ncontrolled nsubstances.
D. APRNs nare nable nto nprescribe nindependently nin nall nstates, nwhereas na
nphysician’s nassistant nneeds nto nhave na nphysician nsupervising ntheir
npractice.
ANS: n B PTS: n n1
3. Clinical njudgment nin nprescribing nincludes:
A. Factoring nin nthe ncost nto nthe npatient nof nthe nmedication nprescribed
B. Always nprescribing nthe nnewest nmedication navailable nfor nthe ndisease nprocess
C. Handing nout ndrug nsamples nto npoor npatients
D. Prescribing nall ngeneric nmedications nto ncut ncosts
ANS: n A PTS: n n1
4. The nprocess nfor nchoosing nan neffective ndrug nfor na ndisorder nincludes:
A. Asking nthe npatient nwhat ndrug nthey nthink nwould nwork nbest nfor nthem
B. Consulting nnationally nrecognized nguidelines nfor ndisease nmanagement
C. Prescribing nmedications nthat nare navailable nas nsamples nbefore nwriting na nprescription
D. Following nU.S. nDrug nEnforcement nAdministration nguidelines nfor nprescribing
ANS: n B PTS: n n1
5. Nonintentional nnonadherence nof ndrug ntherapy nmay noccur ndue nto:
A. Belief nthat nmedication ndoes nnot nwork
B. Adverse ndrug nreactions
C. Chronic nconditions nthat nrequire ndaily ntherapy
D. Forgetfulness nor ndistraction
ANS: n D PTS: n n1
